LA-based Kite Pharma, a fledgling biotech that has set out to develop new cancer vaccine therapies, has raised $15 million in Series A venture cash. The company will use the funding to support development of its preclinical pipeline and work on its Phase I therapeutic vaccine for hepatocellular cancer. Kite release
Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes
Wednesday, March 24 | 2pm ET / 11am PT
Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.